These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 28432587

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
    Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio MS, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy ML, Hoang-Xuan K.
    Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
    [Abstract] [Full Text] [Related]

  • 4. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
    Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A.
    J Clin Oncol; 2013 Nov 01; 31(31):3971-9. PubMed ID: 24101038
    [Abstract] [Full Text] [Related]

  • 5. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
    Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE.
    J Clin Oncol; 2007 Oct 20; 25(30):4730-5. PubMed ID: 17947720
    [Abstract] [Full Text] [Related]

  • 6. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
    Sun X, Liu J, Wang Y, Bai X, Chen Y, Qian J, Zhu H, Liu F, Qiu X, Sun S, Ji N, Liu Y.
    Oncotarget; 2017 Jul 25; 8(30):49156-49164. PubMed ID: 28467782
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
    Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS.
    Blood; 2015 Feb 26; 125(9):1403-10. PubMed ID: 25568347
    [Abstract] [Full Text] [Related]

  • 9. Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
    Alcantara M, Chevrier M, Jardin F, Schmitt A, Houillier C, Oberic L, Chinot O, Morschhauser F, Peyrade F, Houot R, Hoang-Xuan K, Ghesquieres H, Soussain C.
    J Hematol Oncol; 2024 Sep 19; 17(1):86. PubMed ID: 39300447
    [Abstract] [Full Text] [Related]

  • 10. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, Fritsch K, Fricker H, Burger E, Grishina O, Valk E, Zucca E, Illerhaus G.
    BMC Cancer; 2016 Apr 21; 16():282. PubMed ID: 27098429
    [Abstract] [Full Text] [Related]

  • 11. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
    Fritsch K, Kasenda B, Hader C, Nikkhah G, Prinz M, Haug V, Haug S, Ihorst G, Finke J, Illerhaus G.
    Ann Oncol; 2011 Sep 21; 22(9):2080-2085. PubMed ID: 21303800
    [Abstract] [Full Text] [Related]

  • 12. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
    Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (IELSG).
    Lancet Haematol; 2016 May 21; 3(5):e217-27. PubMed ID: 27132696
    [Abstract] [Full Text] [Related]

  • 13. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C.
    Orv Hetil; 2009 Oct 18; 150(42):1937-44. PubMed ID: 19812012
    [Abstract] [Full Text] [Related]

  • 14. A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.
    Taoka K, Okoshi Y, Sakamoto N, Takano S, Matsumura A, Hasegawa Y, Chiba S.
    Int J Hematol; 2010 Nov 18; 92(4):617-23. PubMed ID: 20967518
    [Abstract] [Full Text] [Related]

  • 15. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
    Collignon A, Houillier C, Ahle G, Chinot O, Choquet S, Schmitt A, Agape P, Soussain C, Hoang-Xuan K, Tabouret E.
    Ann Hematol; 2019 Apr 18; 98(4):915-922. PubMed ID: 30535802
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study.
    Piriyakhuntorn P, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E, Tantiworawit A, Norasetthada L.
    Int J Clin Oncol; 2021 Oct 18; 26(10):1805-1811. PubMed ID: 34236556
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ.
    Hematol Oncol; 2013 Sep 18; 31(3):143-50. PubMed ID: 23161567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.